Stockreport

Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive Li...

Xilio Therapeutics, Inc.  (XLO) 
PDF Achievement of milestone extends anticipated cash runway into first quarter of 2027 WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasda [Read more]